A business decision was made to discontinue manufacture of the drug product. This product discontinuation is not related to product quality, safety, or efficacy. The anticipated final date for marketing is September 2017.

1.25 mg/250 mg; 500 tablets/bottle (NDC 0115-1648-02)

08/25/2017

A business decision was made to discontinue manufacture of the drug product. This product discontinuation is not related to product quality, safety, or efficacy. The anticipated final date for marketing is September 2017.

2.5 mg/500 mg; 100 tablets/bottle (NDC 0115-1649-01)

08/25/2017

A business decision was made to discontinue manufacture of the drug product. This product discontinuation is not related to product quality, safety, or efficacy. The anticipated final date for marketing is September 2017.

2.5 mg/500 mg; 500 tablets/bottle (NDC 0115-1649-02)

08/25/2017

A business decision was made to discontinue manufacture of the drug product. This product discontinuation is not related to product quality, safety, or efficacy. The anticipated final date for marketing is September 2017.

5 mg/500 mg; 100 tablets/bottle (NDC 0115-1650-01)

08/25/2017

A business decision was made to discontinue manufacture of the drug product. This product discontinuation is not related to product quality, safety, or efficacy. The anticipated final date for marketing is September 2017.

5 mg/500 mg; 500 tablets/bottle (NDC 0115-1650-02)

08/25/2017

A business decision was made to discontinue manufacture of the drug product. This product discontinuation is not related to product quality, safety, or efficacy. The anticipated final date for marketing is September 2017.